Pharmacokinetics and pharmacogenetics in psychiatry;Pharmakokinetik und pharmakogenetik in der psychiatrie

Psycho

Volumn 28, Issue 10, 2002, Pages 534-538

  Lohmann, Petra L ^a   Grasmäder, Katja ^a   Rao, Marie Luise ^a   Hiemke, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cytochrome P450 enzymes; Neurotransmitter receptors; Polymorphism; Psychopharmaca therapy

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; CAFFEINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DONEPEZIL; FLUNARIZINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; SERTRALINE; SPARTEINE; TACRINE; TRAMADOL; UNINDEXED DRUG;

BINDING KINETICS; CATALYSIS; DIAGNOSTIC VALUE; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG METABOLISM; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; INDIVIDUALITY; MEDICAL RESEARCH; MENTAL DISEASE; NEUROTRANSMITTER RELEASE; PHARMACOGENETICS; PHENOTYPE; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0036424869     PISSN: 03407845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Aynacioglu AS, Brockmöller J et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415
2. Dahl ML, Bertilsson L et al. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype. Psychopharmacology 1996; 123: 315-319
3. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491
4. Flockhart DA, Drici MD et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20: 317-324
5. Griese EU, Zanger UM et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26
6. Hiemke c, Weigmann H et al. Evidence based medicine. Therapeutisches Drug Monitoring von Psychopharmaka. Neurotransmitter 2000; 11: 52-55
7. Kidd RS, Straughn AB et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 71-80
8. Kirchheiner J, BrØsen K et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192
9. Lerer B, Segman RH et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119
10. Lessard E, Yessine MA et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21: 175-184
11. Lohmann PL, Rao ML et al. Influence of genotype and medication on the sparteine metabolic ratio of psychiatric patients. Eur J Clin Pharmacol 2001; 57: 289-295
12. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671
13. Ninomiya H, Mamiya K et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22: 230-232
14. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22: 298-305
15. Spina E, Gitto C et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study. Eur J Clin Pharmacol 1997; 51: 395-398
16. Staddon S, Arranz MJ et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 2002; 162: 18-23
17. Steimer W, Müller B, Leucht S, Kissling W. Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 2001; 308: 33-41
18. Wormhoudt LW, Commandeur JN et al. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29: 59-124
19. Zullino DF, Delessert D et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol. 2002; 17: 141-143